<DOC>
	<DOCNO>NCT00707772</DOCNO>
	<brief_summary>Hemophilic patient know high risk group acquire hepatitis C. The surveillance data Ministry Of Health IR.Iran show 60 % infected HCV infection . We try PEGASYS plus Ribavirin Hemophilic patient HCV .</brief_summary>
	<brief_title>PegasysÂ® Plus Ribavirin Hemophilic Patients With Hepatitis C Virus Infection</brief_title>
	<detailed_description>The investigator enroll 400 patient study . The patient receive PEGASYS ( Peginterferon alpha-2a ( 40 KD ) ) 180 microgram per week plus COPEGUS ( Ribavirin ) 800 microgram Genotype 2 3 1000 milligram weight less 75 kg 1200 milligram 75 kg . The duration protocol depend genotype virus . In genotype 1 4 , 48 week genotype 2 3 , 24 week . The patient visit every 4 week biochemistry lab test . The patient check quantitative HCV RNA third month initiation treatment assess early virologic response end study complete response rate six month treatment completion sustain response rate . The patient undetectable HCV RNA consider responder . We omit liver biopsy patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HCV RNA positive Age old 12 year Ongoing pregnancy breast feed Hx HCC Hx alcoholic liver disease Hx bleed esophageal varix Hx hemochromatosis Hx autoimmune hepatitis Hx Suicidal attempt Hx cerebrovascular dis Hx severe retinopathy Hx severe psoriasis Hx scleroderma Hx metabolic liver disease Hx SLE</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Hemophilia</keyword>
	<keyword>Pegasys</keyword>
	<keyword>Ribavirin</keyword>
</DOC>